Maze Therapeutics (MAZE) CSBO exercises options and sells 7,500 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics CSBO Atul Dandekar reported an exercise-and-sell transaction in company stock. On March 30, 2026, he exercised 7,500 stock options at $10.42 per share, acquiring an equal number of Maze Therapeutics common shares.

That same day, he sold a total of 7,500 common shares in two open-market transactions at weighted average prices of $29.2556 and $30.0173 per share, executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owns 10,503 common shares and holds 51,643 stock options that remain outstanding.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($220,019)

Net Sell 4 txns

Insider Dandekar Atul

Role CSBO

Sold 7,500 shs ($220K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,500	$0.00	--
Exercise	Common Stock	7,500	$10.42	$78K
Sale	Common Stock	6,710	$29.2556	$196K
Sale	Common Stock	790	$30.0173	$24K

Holdings After Transaction: Stock Option (Right to Buy) — 51,643 shares (Direct); Common Stock — 18,003 shares (Direct)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.86 to $29.84 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.87 to $30.24 per share, inclusive. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

Key Figures

Options exercised: 7,500 options Exercise price: $10.42 per share Shares sold (first block): 6,710 shares at $29.2556 +4 more

7 metrics

Options exercised 7,500 options Stock Option (Right to Buy) exercised at $10.42 on March 30, 2026

Exercise price $10.42 per share Conversion/exercise price for 7,500 stock options

Shares sold (first block) 6,710 shares at $29.2556 Open-market sale of Maze Therapeutics common stock on March 30, 2026

Shares sold (second block) 790 shares at $30.0173 Additional open-market sale of Maze Therapeutics common stock on March 30, 2026

Common shares after sales 10,503 shares Direct Maze Therapeutics common stock holdings following transactions

Options remaining 51,643 options Stock options outstanding after the 7,500-option exercise

Net shares sold 7,500 shares Net share disposition from exercise-and-sell sequence (transaction summary)

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy, weighted average price, fully vested, +1 more

5 terms

Rule 10b5-1 trading plan financial

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy financial

"security_title: Stock Option (Right to Buy)"

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested financial

"The option is fully vested. Pursuant to the terms of the reporting person's award agreement..."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 04:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CSBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/30/2026		M⁽¹⁾		7,500	A	$10.42	18,003	D
Common Stock	03/30/2026		S⁽¹⁾		6,710	D	$29.2556⁽²⁾	11,293	D
Common Stock	03/30/2026		S⁽¹⁾		790	D	$30.0173⁽³⁾	10,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$10.42	03/30/2026		M⁽¹⁾			7,500	⁽⁴⁾	04/11/2031	Common Stock	7,500	$0	51,643	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.86 to $29.84 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.87 to $30.24 per share, inclusive.

4. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

	/s/ Courtney Phillips, as attorney-in-fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Maze Therapeutics (MAZE) CSBO Atul Dandekar report in this Form 4?

Atul Dandekar reported an exercise-and-sell transaction. He exercised 7,500 Maze Therapeutics stock options at $10.42 per share, then sold 7,500 common shares in open-market trades the same day under a Rule 10b5-1 trading plan.

How many Maze Therapeutics (MAZE) shares did Atul Dandekar sell and at what prices?

He sold 7,500 Maze Therapeutics common shares in two open-market transactions. The weighted average sale prices were $29.2556 per share for 6,710 shares and $30.0173 per share for 790 shares, as disclosed in the Form 4 filing.

How many Maze Therapeutics (MAZE) stock options did Atul Dandekar exercise?

He exercised 7,500 Maze Therapeutics stock options. Each option had an exercise price of $10.42 per share and was already fully vested, with the award having become fully vested on March 17, 2025, according to the Form 4 footnotes.

How many Maze Therapeutics (MAZE) shares does Atul Dandekar hold after these transactions?

After the reported transactions, Atul Dandekar directly holds 10,503 Maze Therapeutics common shares. In addition, he has 51,643 stock options remaining outstanding, providing further potential equity exposure if exercised in the future.

Were Atul Dandekar’s Maze Therapeutics (MAZE) stock sales under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025. Such pre-arranged plans automate trades and can make their timing less indicative of discretionary trading decisions.

What does the fully vested option mean in Atul Dandekar’s Maze Therapeutics (MAZE) Form 4?

The Form 4 notes the option was fully vested, with vesting completed on March 17, 2025. This means Dandekar had earned the right to exercise all 7,500 options and could convert them into Maze Therapeutics common shares at the stated $10.42 exercise price.